Literature DB >> 26826001

Hepatic IGF-1R overexpression combined with the activation of GSK-3β and FOXO3a in the development of liver cirrhosis.

Wentao Liu1, Jing Li2, Yan Cai3, Qiong Wu4, Yue Pan2, Yang Chen1, Yujing Chen2, Xiao Zheng2, Wei Li1, Xuewen Zhang5, Changyong E6.   

Abstract

AIMS: Liver cirrhosis is the common pathological histology manifest among a number of chronic liver diseases and liver cancer. Circulating levels of insulin growth factor-1 (IGF-1) have been recently linked to liver cirrhosis and the development of liver cancer. Herein, we hypothesized that IGF-1R overexpression combining the activation of GSK-3β and FOXO3a were involved in the development of human and murine chronic liver cirrhosis.
METHODS: Liver samples of patients were screened from the Tissue Bank of the China-Japan Union Hospital of Jilin University. Mice liver fibrosis model was performed using intraperitoneal injection of carbon tetrachloride (CCl4) for 12weeks. Serum IGF-1 levels were detected by enzyme-linked immunosorbent assays (ELISA). Microscopical examination of liver parenchyma was performed using conventional H&E and Masson's staining. Moreover, we investigated the IGF-1 receptor (IGF-1R) signaling pathway at different period after CCl4 administration.
RESULTS: Serum IGF-1 levels were significantly decreased in patients with liver cirrhosis, which is concomitant with the declined circulating levels of IGF-1 in 8 to 12weeks CCl4-treated mice. Furthermore, the expression of IGF-1R was significantly higher at 12w compared with control group. In addition, activation of the GSK-3β and FOXO3a were activated during the process of murine chronic liver injury.
CONCLUSION: The present study demonstrates that decreased circulating IGF-1 levels are involved in human and murine chronic liver disease. Interestingly, overexpression of the IGF-1R, and activation of GSK3β and FOXO3a might be the molecular mechanisms underlying the development of liver cirrhosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT; FoxO3a; GSK-3β; IGF-1; IGF-1R; Liver cirrhosis

Mesh:

Substances:

Year:  2016        PMID: 26826001     DOI: 10.1016/j.lfs.2016.01.037

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD.

Authors:  Anna Alisi; Valentina Pampanini; Cristiano De Stefanis; Nadia Panera; Annalisa Deodati; Valerio Nobili; Stefano Cianfarani
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

2.  Fraxin Prevents Chemically Induced Hepatotoxicity by Reducing Oxidative Stress.

Authors:  Bo Yoon Chang; Young Suk Jung; Chi-Su Yoon; Jun Seok Oh; Jae Heoi Hong; Youn-Chul Kim; Sung Yeon Kim
Journal:  Molecules       Date:  2017-04-06       Impact factor: 4.411

3.  Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes.

Authors:  Bo Tu; Jingfeng Bi; Dan Wu; Peng Zhao; Lei Shi; Yangxin Xie; Xin Zhang; Zhe Xu; Suxia Liu; Xinhua Wang; Xiaoxi Li; Fusheng Wang; Enqiang Qin
Journal:  Oncotarget       Date:  2017-12-13

4.  Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis.

Authors:  Yangxin Xie; Bo Tu; Zhe Xu; Xin Zhang; Jingfeng Bi; Min Zhao; Weiwei Chen; Lei Shi; Peng Zhao; Chunmei Bao; Enqiang Qin; Dongping Xu
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

5.  Soluble Klotho Improves Hepatic Glucose and Lipid Homeostasis in Type 2 Diabetes.

Authors:  Huiying Gu; Wei Jiang; Nan You; Xiaobing Huang; Yuming Li; Xuehui Peng; Rui Dong; Zheng Wang; Yinan Zhu; Ke Wu; Jing Li; Lu Zheng
Journal:  Mol Ther Methods Clin Dev       Date:  2020-08-05       Impact factor: 6.698

Review 6.  Glycogen synthase kinase-3β: a promising candidate in the fight against fibrosis.

Authors:  Hanxue Zheng; Zhi Yang; Zhenlong Xin; Yang Yang; Yuan Yu; Jihong Cui; Hongbo Liu; Fulin Chen
Journal:  Theranostics       Date:  2020-09-23       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.